B. Riley Wealth Advisors Inc. Has $4.62 Million Position in Novo Nordisk A/S (NYSE:NVO)

B. Riley Wealth Advisors Inc. lessened its position in Novo Nordisk A/S (NYSE:NVO) by 33.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,482 shares of the company’s stock after selling 20,024 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Novo Nordisk A/S were worth $4,623,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the second quarter valued at $25,000. Gilliland Jeter Wealth Management LLC increased its stake in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter worth about $28,000. Finally, Abound Wealth Management increased its position in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after acquiring an additional 157 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.5 %

Shares of Novo Nordisk A/S stock opened at $106.95 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business has a fifty day simple moving average of $110.59 and a two-hundred day simple moving average of $126.22. Novo Nordisk A/S has a 1 year low of $96.53 and a 1 year high of $148.15. The company has a market capitalization of $479.94 billion, a price-to-earnings ratio of 34.61, a P/E/G ratio of 1.43 and a beta of 0.40.

Analysts Set New Price Targets

Several research analysts recently commented on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $150.40.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.